Repligen (RGEN) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture.Where can I buy shares of RGEN?
Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.Who buys Irgen stock?
RGEN stock was purchased by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Macquarie Group Ltd., Brown Capital Management LLC, Alliancebernstein L.P., Perceptive Advisors LLC, State Street Corp, Baird Financial Group Inc., and Millennium Management LLC.Is Repligen stock a buy or sell?
There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Repligen stock. View analyst ratings for Repligen or view top-rated stocks. What stocks does MarketBeat like better than Repligen?